Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 188

Related Citations for PubMed (Select 23324275)

2.

[Programmed death-1 (PD-1) and PD-L1 expression during antiviral treatment of chronic hepatitis B].

Xie DY, Lin BL, Chen FJ, Deng H, Chong YT, Zhang XH, Gao ZL.

Zhonghua Gan Zang Bing Za Zhi. 2010 Sep;18(9):646-50. doi: 10.3760/cma.j.issn.1007-3418.2010.09.002. Chinese.

PMID:
20943073
3.

Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion.

Evans A, Riva A, Cooksley H, Phillips S, Puranik S, Nathwani A, Brett S, Chokshi S, Naoumov NV.

Hepatology. 2008 Sep;48(3):759-69. doi: 10.1002/hep.22419.

PMID:
18697210
4.

Pegylated interferon α enhances recovery of memory T cells in e antigen positive chronic hepatitis B patients.

Liu YZ, Hou FQ, Ding P, Ren YY, Li SH, Wang GQ.

Virol J. 2012 Nov 16;9:274. doi: 10.1186/1743-422X-9-274.

5.

Efficacy of sequential use of telbivudine in hepatitis B e antigen-positive chronic hepatitis B patients with partial responses to pegylated interferon: a pilot study.

Huang Z, Zhao Z, Zheng Y, Peng L, Lin C, Deng H, Gao Z.

J Viral Hepat. 2013 Apr;20 Suppl 1:52-7. doi: 10.1111/jvh.12064.

PMID:
23458525
6.

[Dynamic changes in programmed death-1 expression on the surface of T cells in chronic hepatitis C patients undergoing interferon therapy].

Dong RQ, Zhou DF, Han R, Zhou JY, Zhao CY, Zhen Z.

Zhonghua Gan Zang Bing Za Zhi. 2013 Dec;21(12):899-902. doi: 10.3760/cma.j.issn.1007-3418.2013.12.005. Chinese.

PMID:
24636290
7.

Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.

Sonneveld MJ, Rijckborst V, Cakaloglu Y, Simon K, Heathcote EJ, Tabak F, Mach T, Boucher CA, Hansen BE, Zeuzem S, Janssen HL.

Antivir Ther. 2012;17(1):9-17. doi: 10.3851/IMP1887.

PMID:
22267464
8.

Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy.

Tseng TC, Yu ML, Liu CJ, Lin CL, Huang YW, Hsu CS, Liu CH, Kuo SF, Pan CJ, Yang SS, Su CW, Chen PJ, Chen DS, Kao JH.

Antivir Ther. 2011;16(5):629-37. doi: 10.3851/IMP1841.

PMID:
21817184
9.

[Relationship between the changes in immune cells and HBeAg loss following antiviral treatment in chronic hepatitis B patients].

Zheng Q, Zhu YY, Chen J, Liu YR, You J, Zeng DW, Lin S, Jiang JJ.

Zhonghua Gan Zang Bing Za Zhi. 2012 Nov;20(11):801-6. doi: 10.3760/cma.j.issn.1007-3418.2012.11.001. Chinese.

PMID:
23206296
10.

Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

Wong VW, Wong GL, Yan KK, Chim AM, Chan HY, Tse CH, Choi PC, Chan AW, Sung JJ, Chan HL.

Hepatology. 2010 Jun;51(6):1945-53. doi: 10.1002/hep.23568.

PMID:
20209602
11.

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

Shepherd J, Jones J, Takeda A, Davidson P, Price A.

Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.

12.

[Factors influencing the curative effect in patients with HBeAgpositive chronic hepatitis B treated with peg-interferon α-2a].

Chen J, Zheng Q, Jiang J, Zheng J.

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2012 Jul;37(7):714-9. doi: 10.3969/j.issn.1672-7347.2012.07.012. Chinese.

13.

Hepatitis B e-antigen persistency is associated with the properties of HBV-specific CD8 T cells in CHB patients.

Peng G, Luo B, Li J, Zhao D, Wu W, Chen F, Chen Z.

J Clin Immunol. 2011 Apr;31(2):195-204. doi: 10.1007/s10875-010-9483-5. Epub 2010 Dec 1.

PMID:
21120686
14.

Peginterferon-α does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis.

Penna A, Laccabue D, Libri I, Giuberti T, Schivazappa S, Alfieri A, Mori C, Canetti D, Lampertico P, Viganò M, Colombo M, Loggi E, Missale G, Ferrari C.

J Hepatol. 2012 Jun;56(6):1239-46. doi: 10.1016/j.jhep.2011.12.032. Epub 2012 Feb 9.

PMID:
22326467
15.

Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B.

Sonneveld MJ, Arends P, Boonstra A, Hansen BE, Janssen HL.

J Hepatol. 2013 May;58(5):898-903. doi: 10.1016/j.jhep.2013.01.029. Epub 2013 Jan 29.

PMID:
23376362
16.

Treatment with telbivudine positively regulates antiviral immune profiles in Chinese patients with chronic hepatitis B.

Ma L, Cai YJ, Yu L, Feng JY, Wang J, Li C, Niu JQ, Jiang YF.

Antimicrob Agents Chemother. 2013 Mar;57(3):1304-11. doi: 10.1128/AAC.02181-12. Epub 2012 Dec 28.

17.

Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients.

Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, Dauvergne A, Asselah T, Boyer N, Bedossa P, Valla D, Vidaud M, Nicolas-Chanoine MH, Marcellin P.

Hepatology. 2009 Apr;49(4):1151-7. doi: 10.1002/hep.22744.

PMID:
19115222
18.

Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.

Takkenberg B, Terpstra V, Zaaijer H, Weegink C, Dijkgraaf M, Jansen P, Beld M, Reesink H.

J Gastroenterol Hepatol. 2011 Oct;26(10):1527-35. doi: 10.1111/j.1440-1746.2011.06766.x.

PMID:
21557773
19.

HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B.

Fried MW, Piratvisuth T, Lau GK, Marcellin P, Chow WC, Cooksley G, Luo KX, Paik SW, Liaw YF, Button P, Popescu M.

Hepatology. 2008 Feb;47(2):428-34. doi: 10.1002/hep.22065.

PMID:
18220290
20.

[HBV-specific CD8+ T cells for sustained HBeAg seroconversion after lamivudine therapy].

Lee CK, Han KH, Suh JH, Cho YS, Won SY, Chon CY, Moon YM, Park IS.

Korean J Hepatol. 2005 Mar;11(1):34-42. Korean.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk